Navigation Links
Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
Date:8/27/2013

Oro Valley, AZ (PRWEB) August 27, 2013

Convoy Therapeutics, Inc. has been selected to present at the 2013 Rocky Mountain Life Science Investor and Partnering Conference. The conference will take place on September 18-19, 2013 in Denver, Colorado and is hosted by the Colorado BioScience Association. Convoy Therapeutics is one company among a field of just thirty from Colorado, Arizona, Utah, Montana, and New Mexico that was chosen to present.

Convoy Therapeutics is a subsidiary of ACTUS Biotechnologies, Inc., an accelerator focused on development of novel technologies into commercially available therapies. The Convoy Therapeutics platform technology is based upon a family of peptides, including the proprietary "SPACE" (Skin Penetrating and Cell Entering) peptide. Studies using the peptide in topical formulations with and without covalent attachment have demonstrated an exceptional ability to deliver molecules as large as 1.6 megadaltons past the stratum corneum and into the deeper layers of the skin. Additionally, the technology is capable of creating reservoirs of small molecules, enhancing retention and decreasing dosing frequency, and a demonstrated ability to enhance the penetration of nucleic acids into the skin and cells.

The Convoy Therapeutics platform technology has an enormous range of potential applications in the pharmaceutical, medical aesthetic, cosmetic and vaccine industries, including the opportunity to transform current oral and intravenous drugs into topical formulations for the treatment of dermatological and other diseases.

The company’s lead programs include a topical cosmetic Hyaluronic Acid product for the reduction of fine lines and wrinkles for use between filler or toxin injections, and CycloPsorb™, a topical cyclosporine prescription product for the treatment of psoriasis. The platform is also being investigated with a number of pharmaceutical and cosmetic partners for use with a variety of large and small molecules. Given the challenge that topical macromolecule delivery has posed to the pharmaceutical industry for so many years, the results of the Convoy Therapeutics platform have been remarkable.

For more information on Convoy Therapeutics, visit the company’s website here. For information on ACTUS Biotechnologies, visit the company’s website here. Additional information on the Rocky Mountain Life Science Investor and Partnering Conference can be found here.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11063671.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
2. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
3. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
4. AML Therapeutics Market in the 6MM Worth $430.7m in 2017 Says a New Research Report Available at ReportsnReports.com
5. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
6. Oncology Therapeutics Market in India to 2018 Report
7. PTC Therapeutics Announces Achievement Of Major Milestone In SMA Collaboration
8. NuMe Health Becomes MicroBiome Therapeutics And Recruits New CEO
9. Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
10. Sorrento Therapeutics Announces Reverse Split of Common Stock
11. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trius Therapeutics, Inc. - TSRX
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... Inc., will hold an open house for regional manufacturers at its Maple Grove, ... from Tsugami, Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 leading suppliers ...
(Date:4/27/2016)... , April 27, 2016 ... (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... an ihre Pressemitteilung vom 13. August 2015 die ... ihre Finanzen um zusätzliche 200.000.000 Einheiten auf 400.000.000 ... Dollar zu bringen. Davon wurden 157.900.000 Einheiten mit ...
(Date:4/27/2016)... Winnipeg, Manitoba (PRWEB) , ... April 27, 2016 ... ... commercially released for simultaneous preclinical PET (Positron Emission Tomography) and MRI (Magnetic Resonance ... for better understanding disease and testing novel treatments in small animal subjects. Simultaneous ...
(Date:4/26/2016)... ... April 27, 2016 , ... Cameron Cushman ... as an associate in the firm’s Intellectual Property practice group. , Clients turn ... patent applications. He has an electrical engineering and computer engineering background, and experience ...
Breaking Biology Technology:
(Date:3/18/2016)... 2016 --> --> ... Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & ... the border security market and the continuing migration crisis in ... Europe has led visiongain to publish this unique ... --> defence & security companies in the border ...
(Date:3/15/2016)... , March 15, 2016 Yissum ... , the technology-transfer company of the Hebrew University, announced ... of remote sensing technology of various human biological indicators. ... raising $2.0 million from private investors. ... based on the detection of electromagnetic emissions from sweat ...
(Date:3/11/2016)... 2016 http://www.apimages.com ) - --> ... available at AP Images ( http://www.apimages.com ) - ... to produce the new refugee identity cards. DERMALOG will be unveiling ... in Hanover next week.   --> ... used to produce the new refugee identity cards. DERMALOG will be ...
Breaking Biology News(10 mins):